ARYA Sciences Acquisition Corp. III (ARYA)
|Net Income (ttm)||n/a|
|Trading Day||May 13|
|Day's Range||9.88 - 10.15|
|52-Week Range||9.82 - 25.89|
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology appoints Matt Murphy, former 10x Genomics and Pacific Biosciences executive, as General Counsel
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III ("AR...
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Co...
SEATTLE & NEW YORK--(BUSINESS WIRE)--Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human pro...
ARYA Sciences Acquisition Corp III does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in New York, New York.
|IPO Date |
Aug 7, 2020
|Stock Exchange |
|Ticker Symbol |